Marshall Wace
TNGX icon

Marshall Wace’s Tango Therapeutics TNGX Stock Holding History

Marshall Wace’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-329,231
Closed -$2.92M – 3678
2025
Q4 		$2.92M Sell
329,231
-1,160,287
-78% -$10M ﹤0.01% 1400
2025
Q3 		$12.5M Sell
1,489,518
-253,173
-15% -$1.71M 0.01% 835
2025
Q2 		$8.92M Sell
1,742,691
-99,472
-5% -$246K 0.01% 890
2025
Q1 		$2.52M Buy
+1,842,163
New +$4.52M ﹤0.01% 1370
2024
Q4 		– Sell
-73,122
Closed -$563K – 3009
2024
Q3 		$563K Buy
+73,122
New +$698K ﹤0.01% 1878
2024
Q2 		– Sell
-109,269
Closed -$868K – 2965
2024
Q1 		$868K Buy
+109,269
New +$1.17M ﹤0.01% 1711
2022
Q2 		– Sell
-28,915
Closed -$220K – 3847
2022
Q1 		$220K Buy
28,915
+22,646
+361% +$196K ﹤0.01% 3069
2021
Q4 		$68K Buy
+6,269
New +$75.4K ﹤0.01% 3485

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Marshall Wace's TNGX Position: Q1 2026 in Review

Marshall Wace sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 329,231 shares — an estimated $2.92M sold.

Marshall Wace first reported a position in TNGX in Q4 2021 and held it in 8 quarters. The position peaked at $12.5M in Q3 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Marshall Wace reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 329,231 Tango Therapeutics shares in Q1 2026, an estimated $2.92M.
  • Marshall Wace first reported a position in Tango Therapeutics in Q4 2021 and held it in 8 quarters.
  • Marshall Wace's Tango Therapeutics position peaked at $12.5M in Q3 2025.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.